Welcoming 2025—A Year of Collaboration and Progress

As we begin 2025, it is a time to reflect on our journey and the exciting initiatives that continue to shape the future of Thrombosis & Haemostasis. This editorial offers a moment to celebrate recent achievements and introduce the new strategies, collaborations, and opportunities we look forward to in the year ahead.

Impact Factor: A Reflection of Commitment

Our Impact Factor stands at 5.0, a slight decline from last year's 6.7. Although this drop reflects broader post-Covid trends and the growing number of scientific journals, we note that the decrease was less pronounced than for many others in the field. The journal now ranks 18th out of 97 journals in Hematology (previously 15th out of 79) and 13th out of 96 in Peripheral Vascular Disease (previously 11th out of 67). We remain proud of our ability to maintain a competitive position while prioritizing the quality and integrity of our publications.

Editorial Board

As part of our ongoing commitment to excellence, we are deeply grateful for the dedication and expertise of our Editorial Board members, who continue to guide the journal's direction and shape its content. This year, we bid farewell to two esteemed Editorial Board members, Vera Ignjatovic and Sam Schulman, both of whom have played pivotal roles in advancing the journal and shaping its trajectory over the years. We extend our heartfelt gratitude for their invaluable service and wish them all the best in their future endeavors.

We also want to express our sincere thanks to all our reviewers who continued to provide high-quality, timely feedback during 2024. We would like to specifically acknowledge the outstanding efforts of our top reviewers for 2024: Luis Jara-Palomares, Nicola Mumoli, Eva Soler, Benilde Cosmi, and Young-Hoon Jeong.

New and Ongoing Initiatives

One of the most significant developments in the past year has been the creation of our Strategy Board, which brings together a select group of junior and more senior Section Editors for regular discussions on the direction of the journal's editorial strategies. These meetings have fostered the development of new initiatives as well as helped us to address emerging challenges in the world of scientific publishing including concerns around data integrity.

Initiatives from our Editorial Board led to publications of critical manuscripts, ranging from expert analyses on the new 2024 ESC guidelines[1] and on appropriate use of direct oral anticoagulants (DOACs)[2] to Executive Summaries of the Chinese Guidelines on atrial fibrillation in older adults[3] and of the Scottish Intercollegiate Guidelines Network (SIGN) on dementia biomarkers.[4]

We were also very excited to publish the first paper in a series of EU consortia studies, the TARGET study[5] delivering valuable perspectives on Personalised Management of Atrial Fibrillation-Related Stroke via the Health Virtual Twins Technology and Artificial Intelligence. Other valuable contributions included a mini-review on monocyte subsets in cardiovascular disease,[6] a timely and informative piece on biomarkers. As we move into 2025, we anticipate more state-of-the-art reviews and position papers on cutting-edge topics and are exploring new formats for the journal, bringing together leading experts across emerging topics.

Enhancing Access, Engagement, and Visibility

Expanding access to high-quality research remains a priority for the journal. In 2025, we are pleased to announce that Thrombosis & Haemostasis now offers free publishing for authors, with no page or color charges. This initiative aims to reduce the barriers to publication, allowing researchers from all backgrounds to submit their work without financial concerns.

We also continue to make selected articles freely accessible to the global scientific community to reach a broad and diverse audience. Papers highlighted in this editorial, along with those featured in Editors' Choice[7] and the Thrombosis Day Editorial,[8] are available for free.

Our visibility across social media platforms continues to grow. The dedication of our Social Media Editors—Laura Parma, Daniele Pastori, and Giulio Francesco Romiti who joined Jose Rivera-Caravaca earlier last year—has been instrumental in this progress. Their efforts have led to a significant boost in posts and engagement, which we are pleased to see resonating with our audience.

We are also excited to share that Thrombosis & Haemostasis is now active on Bluesky as the social media platform is being quickly embraced by the scientific community. We hope this space will provide our community of researchers, clinicians, and scholars a new forum for discussion and connection and will become an essential part of our outreach efforts, complementing our presence on X and LinkedIn social media platforms. Additionally, we continue to look for ways to improve how we disseminate and share research. Plans for podcasts, in collaboration with Vasculearn (formerly North American Thrombosis Forum, NATF), are in the works, offering a new avenue to engage with experts on critical topics such as atrial fibrillation, anticoagulation therapy, and risk assessment in VTE.

Additionally, we continue to offer seamless transfer to our open-access companion journal, TH Open , which has made significant strides last year. We are pleased to have been able to work in close collaboration with Rory Koenen who took the Editor-in-Chief position of TH Open last year. We expect that inclusion in the Emerging Sources Citation Index (ESCI), in addition to its indexation in PubMed, will enhance the visibility of the journal and ensure its research is widely accessible.

Looking Ahead

Finally, we thank Laura Ambrosius, who joined the Editorial Office earlier this year, for her work alongside Anne Rigby, providing valuable input and strengthening our workflows. We also extend a warm welcome to Shelley Allen, who joined Thieme Science as Executive Publisher at the end of last year and has been working closely with Katrin Maier and Elinor Switzer to support the journal's continued growth.

On behalf of the entire Editorial team, including our colleagues in the Editorial Office and Thieme Science, we would like to express our deepest gratitude for your continued trust and support. Together with our dedicated Section Editors and reviewers, we remain committed to maintaining the highest standards of scientific integrity, delivering quality content, and supporting your valuable contributions to the field.

Conflict of Interest

G.Y.H.L. is a consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, and Anthos. No fees are received personally. He is a National Institute for Health and Care Research (NIHR) Senior Investigator and Co-Principal Investigator of the AFFIRMO project on multimorbidity in AF, funded by the European Union's Horizon 2020 research and innovation program under grant agreement No. 899871.

^* These authors serve as co-corresponding authors.

• References

• 1 Potpara T, Romiti GF, Sohns C. The 2024 European Society of Cardiology Guidelines for diagnosis and management of atrial fibrillation: a viewpoint from a practicing clinician's perspective. Thromb Haemost 2024; 124 (12) 1087-1094
• 2 Bejjani A, Bikdeli B. Direct oral anticoagulants: quick primer on when to use and when to avoid. Thromb Haemost 2024; (e-pub ahead of print).
• 3 Wang Y, Guo Y, Qin M. et al; Expert Reviewers. 2024 Chinese Expert Consensus Guidelines on the diagnosis and treatment of atrial fibrillation in the elderly, endorsed by Geriatric Society of Chinese Medical Association (Cardiovascular Group) and Chinese Society of Geriatric Health Medicine (Cardiovascular Branch): executive summary. Thromb Haemost 2024; 124 (10) 897-911
• 4 Mackay GA, Gall C, Jampana R, Sleith C, Lip GYH. SIGN Dementia Guideline Development Group. Scottish Intercollegiate Guidelines Network guidance on dementia: the investigation of suspected dementia (SIGN 168) with focus on biomarkers—executive summary. Thromb Haemost 2024; (e-pub ahead of print).
• 5 Ortega-Martorell S, Olier I, Ohlsson M, Lip GYH. TARGET Consortium. TARGET: a major European project aiming to advance the personalised management of atrial fibrillation-related stroke via the development of health virtual twins technology and artificial intelligence. Thromb Haemost 2024; (e-pub ahead of print).
• 6 Hristov M, Weber C. Monocyte subsets in cardiovascular disease: a biomarker perspective. Thromb Haemost 2024; (e-pub ahead of print).
• 7 Weber C, Rigby A, Lip GYH. Thrombosis and Haemostasis 2024 Editors' Choice Papers. Thromb Haemost 2025; 125 (01) 85-91
• 8 Rigby A, Albisetti M, Favaloro EJ. et al. Reflections on World Thrombosis Day 2024. Thromb Haemost 2024; (e-pub ahead of print).

Publication History

Article published online:
03 January 2025